Cel-Sci Corp reports a Return on Equity (ROE) of -330.21%.

What is CVM's dividend yield?

Cel-Sci Corp offers a dividend yield of 0.00%.

What is CVM's Quality Score?

Our AI rates CVM's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CVM?

Our AI Timing Score for CVM is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CVM belong to?

Cel-Sci Corp is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Cel-Sci Corp (CVM) Stock Price, Quality Score & AI Analysis

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CVM AI Analysis Summary

Our AI summary for CVM: Cel-Sci Corp (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -330.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CVM

Cel-Sci Corp

US:NYSE MKT STOCK Healthcare >> Biotechnology News 77

USD 1.16

-0.06 (-4.92%) Day Change

Watchlist Portfolio Compare Chart

0.38

D/E

-330.2%

ROE

-128.2%

ROA

0.00%

Div Yield

CEL-SCI CORP
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 1.16 Price -0.06 (-4.92%) Day Change	NEWS SCORE: 77

CVM, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	77
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.16
PBV / Sector	3.10 / 5.20
Earning Per Share	-1.24

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.42 M GREAT
Average 1W Daily Value	0.17 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-128.20 / 27.02
ROA Average (%) / Sector	-99.99 / -368.17
ROA Change Average (%) / Sector	16.65 / 5,404.12 GOOD
ROE (%) / Sector	-330.21 / 3.47
ROE Average (%) / Sector	-212.51 / 6.51
ROE Change Average (%) / Sector	43.69 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:41
Symbol	CVM
Name	CEL-SCI CORP
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	17.48 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	21.32 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182

Phone: 703 506 9460

Website: https://cel-sci.com

Sector: Healthcare >> Biotechnology

Description: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.